Max India Limited MAXIND NSEPHARMA

Healthcare · Medical Care Facilities · India

https://www.maxindia.com

Max India Limited provides services related to senior living communities in India. It operates through four segments: Business Investments, Senior Living, Assisted Care, and Others. The company engages in the treasury investments and investment property businesses. It also offers senior living services. In addition, the company caters to the seniors by providing care at home services and care homes facilities, as well as offers Antara AGEasy, which is a new-age holistic direct to consumer platform that helps seniors manage common chronic conditions. Further, it offers daily living/specialized care/memory care services for seniors; and management and consultancy and shared services, as well as MedCare products. Additionally, the company engages in the learning and development activities; construction and leasing of senior living communities; and management of investments activities. The company was formerly known as Advaita Allied Health Services Limited. Max India Limited was incorporated in 2019 and is based in Gurugram, India.

Market & Price

Market Cap

₹841.21 Cr

Current Price

₹160.16

High / Low (52W)

₹224.11 / ₹122.85

Beta

0.41

Valuation

Stock P/E

Industry PE

37.60

Forward P/E

PEG Ratio

Book Value

₹89.40

Price to Book

1.79

P/S

4.56

EV/EBITDA

-6.47

Dividend Yield

Profitability & Returns

ROCE

-27.95%

ROE

ROA

Profit Margin

-80.64%

Op Margin

-59.39%

EPS (Latest Qtr)

₹-8.17

EPS (TTM)

₹-29.76

Balance Sheet & Liquidity

Debt/Equity

0.44

Quick Ratio

Current Ratio

Debt

₹203.75 Cr

Total Assets

₹632.85 Cr

Current Assets

₹260.52 Cr

Working Capital

₹95.27 Cr

Ownership

Promoter Holding

59.61%

Chg in Prom Hold

FII / Inst Holding

0.12%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹752.76 Cr

Total Revenue (TTM)

₹184.35 Cr

EBITDA

₹-116.30 Cr

Free Cash Flow

Operating Cash Flow

Shares Outstanding

₹5.25 Cr

Gross Margin

71.02%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-8.21%

Profit 5Y

-256.69%

Revenue (YoY)

27.40%

Earnings (YoY)

PROS

No notable strengths flagged.

CONS

Revenue declined at -8.2% CAGR over 5 years.
Earnings shrank at -256.7% CAGR over 5 years.
Trading 28.5% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	MAXIND Max India Limited NSEPHARMA	160.16	-	₹841.21 Cr	-	-27.95%	-	-8.21%	-256.69%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Revenue	-	34.74 Cr	41.52 Cr	36.67 Cr	45.16 Cr	43.10 Cr
Cost of Revenue	-	9.76 Cr	17.43 Cr	8.75 Cr	14.42 Cr	12.83 Cr
Gross Profit	-	24.98 Cr	24.09 Cr	27.92 Cr	30.74 Cr	30.27 Cr
Operating Expenses	-	56.60 Cr	65.87 Cr	61.54 Cr	66.94 Cr	66.56 Cr
Operating Income	-	-31.62 Cr	-41.79 Cr	-33.62 Cr	-36.20 Cr	-36.29 Cr
EBITDA	-	-37.34 Cr	-37.39 Cr	-15.37 Cr	-26.03 Cr	-31.88 Cr
Interest Expense	-	2.04 Cr	2.65 Cr	3.52 Cr	4.06 Cr	3.45 Cr
Pretax Income	-	-44.41 Cr	-45.30 Cr	-24.66 Cr	-36.03 Cr	-41.42 Cr
Tax Provision	-	19.00 L	79.05 L	98.00 L	-1.96 Cr	1.43 Cr
Net Income	-	-44.60 Cr	-46.09 Cr	-25.64 Cr	-34.07 Cr	-42.85 Cr
Diluted EPS	-5.27	-10.03	-	-5.44	-6.52	-8.17

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Revenue	188.13 Cr	201.03 Cr	175.63 Cr	145.49 Cr
Cost of Revenue	129.04 Cr	91.42 Cr	63.53 Cr	36.34 Cr
Gross Profit	59.09 Cr	109.61 Cr	112.10 Cr	109.15 Cr
Operating Expenses	106.87 Cr	109.26 Cr	173.54 Cr	243.23 Cr
Operating Income	-47.79 Cr	35.31 L	-61.45 Cr	-134.09 Cr
EBITDA	-1.69 Cr	11.65 Cr	-34.32 Cr	-111.87 Cr
Interest Expense	9.25 Cr	6.21 Cr	4.56 Cr	7.88 Cr
Pretax Income	-18.03 Cr	-3.01 Cr	-49.03 Cr	-138.58 Cr
Tax Provision	-1.89 Cr	7.37 Cr	7.34 Cr	1.81 Cr
Net Income	-16.14 Cr	-10.38 Cr	-56.38 Cr	-140.39 Cr
Diluted EPS	-2.83	-2.06	-12.36	-30.70

Compounded Sales Growth

5 Years:	-8.21%
1 Year:	27.40%

Compounded Profit Growth

5 Years:	-256.69%
1 Year:	-

Stock Price Performance

1 Year:	-12.02%
6 Months:	-19.00%
3 Months:	-0.32%
1 Month:	-0.37%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Assets	858.32 Cr	753.40 Cr	684.34 Cr	632.85 Cr
Current Assets	549.17 Cr	459.13 Cr	343.25 Cr	260.52 Cr
Cash & Equivalents	13.78 Cr	88.73 Cr	116.03 Cr	22.70 Cr
Inventory	130.36 Cr	51.01 Cr	6.13 Cr	16.64 Cr
Receivables	5.71 Cr	2.86 Cr	4.94 Cr	22.20 Cr
Total Liabilities	216.95 Cr	211.29 Cr	192.00 Cr	274.16 Cr
Current Liabilities	153.19 Cr	161.44 Cr	138.84 Cr	165.25 Cr
Long Term Debt	38.98 Cr	22.34 Cr	81.89 L	93.82 L
Total Debt	60.76 Cr	45.30 Cr	43.57 Cr	102.30 Cr
Total Equity	641.37 Cr	542.11 Cr	492.34 Cr	358.69 Cr
Shares Outstanding	5.69 Cr	4.56 Cr	4.57 Cr	4.61 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Operating Cash Flow	66.50 Cr	69.42 Cr	-102.34 Cr	-127.60 Cr
Investing Cash Flow	17.50 Cr	124.07 Cr	158.64 Cr	46.82 Cr
Financing Cash Flow	-93.94 Cr	-118.54 Cr	-29.00 Cr	-12.55 Cr
Capital Expenditure	-3.02 Cr	-3.66 Cr	-28.75 Cr	-35.88 Cr
Free Cash Flow	63.48 Cr	65.75 Cr	-131.10 Cr	-163.48 Cr
Net Change in Cash	-9.94 Cr	74.94 Cr	27.30 Cr	-93.34 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Gross Margin %	31.4%	54.5%	63.8%	75.0%
Operating Margin %	-25.4%	0.2%	-35.0%	-92.2%
Net Margin %	-8.6%	-5.2%	-32.1%	-96.5%
ROE %	-2.5%	-1.9%	-11.5%	-39.1%
ROCE %	-6.8%	0.1%	-11.3%	-28.7%

Shareholding Pattern

Insiders

59.61%

Institutions

0.12%

Public Float

0.29%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MAXIND

No recent headlines available.

MAXIND · Healthcare